Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968599 · ClinicalTrials.gov registry record
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 2,731
- Enrollment target
NCT05968599 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 2,731 participants.
The verdict
NCT05968599 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 2,731 participants
- Enrollment target
Study Summary
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Most prostate cancers need male sex hormones, such as testosterone, to grow. Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels is known as "castration-resistant". Metastatic cancer is a cancer that has spread to other parts of the body. This is a real-world study, not a clinical trial. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from the Flatiron Electronic Health Record (EHR) database. The study will include patients' information from the database for men who: * Were confirmed by medical tests to have mCRPC * Started first-line treatment with enzalutamide or abiraterone (index date) for mCRPC * Had not received chemotherapy treatment before index date * Were 18 years of age or older on index date Men who are part of this study will receive enzalutamide or abiraterone as part of their usual treatment for mCRPC. We will compare the following between men receiving enzalutamide and men receiving abiraterone: * time from treatment start until death, * treatment duration, and * time to next treatment. This study will use patient information from the database until the end of information that is available.
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,731 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2025-02-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05968599
The ClinicalTrials.gov registry entry for NCT05968599 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,731 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT05968599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05968599 about?
NCT05968599 is a clinical study titled "A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer". The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that ...
What is the current status of trial NCT05968599?
This trial is currently completed. The enrollment target is 2,731 participants. The study started on 2023-07-24. Estimated completion is 2025-02-14.
What interventions are being tested in trial NCT05968599?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT05968599?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.